Posts

Merck–Moderna Cancer-Vaccine Trial Win Sends Stocks Higher

on

Merck–Moderna Personalized Cancer Vaccine Shows Positive Phase 3 Results

on

Vaccine Makers and Experts Reject Trump’s Push to Split MMR Shot

on

Merck's anti‑TL1A antibody tulisokibart scores a win in hidradenitis suppurativa but fails in a rare lung disease (SSc‑ILD), August 2026

on

Merck advances sac-TMT/Keytruda combo in NSCLC as Keytruda patent cliff looms

on

Gilead and Merck Release Key HIV Data

on

Merck’s Lipfendra becomes world’s first oral PCSK9 treatment approved by FDA

on

Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first

on

Kelun's sac-TMT scores win in first-line PD-L1-negative NSCLC population missing from Merck's KEYTRUDA phase 3 program

on

AstraZeneca pays Sino $200M upfront, up to $1.9B for COPD challenger to Merck’s Ohtuvayre

on

Merck Posts Encouraging Phase 3 Ulcerative Colitis Data But Roche Challenge Looms

on

Merck’s IBD Drug from $10.8B Prometheus Deal Claims First Phase 3 Win

on

Portal Biotechnologies raises $9M for cell engineering tech that’s attracted Merck & Co., AbbVie

on

Friday Five: Verges neuro drug-to-data pivot

on

Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact

on

ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer

on

Roche's Tecentriq, Pfizer/Astellas' Padcev and Merck's Keytruda in Bladder Cancer Battle: Recent Updates

on

Merck's ADC sac‑TMT gets its first global Phase 3 win ahead of schedule

on

Merck & Co.'s Keytruda Posts $8B in Q1 2026 as Qlex Picks Up Steam

on

Recent Pharma News: Novo Nordisk's Oral Semaglutide for Kids, Altimmune $225M Offering, Merck-Google Cloud Partnership

on